Abstract: . . .  CE. Inihibtion of the renin-angiotensin system with particular reference to dual blockade treatment. JRAAS, 2001, 2 : 146-152. 50. M UIRHEAD N, F EAGAN BF, M AHON J et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus : A placebo-controlled trial. Current Therapeutic Res, 1999, 60 : 650-660. 51. L ACOURCIRE Y, B LANGER A, G ODIN C et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int, 2000, 58 : 762-769. Page 17 NPHROLOGIE ET HYPERTENSION 277 52. E SMATJES E, F LORES L, I NIGO P et al. Effect of losartan on TGF-1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant, 2001, 16 (S1) : 90-93. 53. L OZANO JV, L LISTERRI JL, A ZNAR J et al. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant, 2001, 16 (S1) : 85-89. 54. P ARVING HH, L EHNERT H, B ROCHNER -M ORTENSEN J et al. The effect of Irbesartan on the develop- . . .
. . .  LISTERRI JL, A ZNAR J et al. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant, 2001, 16 (S1) : 85-89. 54. P ARVING HH, L EHNERT H, B ROCHNER -M ORTENSEN J et al. The effect of Irbesartan on the develop- ment of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 2001, 345 : 870-879. 55. M OGENSEN CE, A NDERSEN NH. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers : Evidence for and against the combination in the treatment of hypertension and proteinuria. Current Hypertension Reports, 2002, 4 : 394-402. 56. A ZZIZI M, C HATELLIER G, G UYENE TT et al. Additive effects of combined angiotension-convertering enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium- depleted normotensives. Circulation, 1995, 92 : 825-834. 57. B ARUCH L, A NAND I, C OHEN IS et al. for the Vasodilator Heart Failure Trial (V-HeFT) Study Group. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation, 1999, . . .
--3000,2,750,3167,58829